Lexicon Pharmaceuticals, Inc.
sotagliflozin
hypertrophic cardiomyopathy (HCM)
Countdown
267days
Phase 3 readout · ~ Mar 31, 2027 estimated
What's at stake
Phase 3 trial results for sotagliflozin in hypertrophic cardiomyopathy (HCM) are due ~ Mar 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company previously announced that the SONATA-HCM pivotal Phase 3 study evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM) is targeting enrollment of 500 patients with both obstructive and non-obstructive HCM, with anticipated”